Compare Abeona Therapeutics Inc (ABEO) vs Altria Group Inc (MO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Altria Group Inc — how do they compare? Abeona Therapeutics Inc trades at $6.7 (market cap $373.32M), while Altria Group Inc trades at $72.86 (market cap $121.84B). The key difference: Altria Group Inc is far larger — about 326.4× Abeona Therapeutics Inc's market cap, and Altria Group Inc pays a 5.81% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MO | |
|---|---|---|
Market Cap | $373.32M | $121.84B |
Sector | Health | Consumer Staples |
52-Week High | $7.23 | $74.55 |
52-Week Low | $4.17 | $54.72 |
Enterprise Value | $228.22M | $142.91B |
Dividend Yield | — | 5.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
MO trades at $72.96, up 0.34% today, with a bullish technical signal from moving averages and a neutral RSI near 60. The stock shows strong profitability with a 39.52% net margin and consistent cash flow, though revenue has been flat near $20.1B. Analysts are largely positive, with 62% recommending Buy and a consensus target of $70.75. Recent news highlights its appeal as a dividend king for income investors, with a $1.06 dividend paid in July 2026.
Outlook: MO offers stable income with high margins and dividend reliability, but faces risks from debt levels and regulatory pressures. The stock is near analyst targets, suggesting limited upside, yet remains a defensive hold for yield-seeking portfolios amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
